The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...

AbbVie ABBV remains a dominant force in the immunology space, powered by the continued uptake of its two blockbuster ...

AbbVie has received the U.S. Food and Drug Administration (FDA) approval for a supplemental new drug application (sNDA) that ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

AbbVie has struck deals with Rinvoq generic hopefuls as it extends protection for one of its prized assets until 2037.

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...

AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...